Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Oct;6(4):256-268.
doi: 10.21037/tp.2017.09.10.

Zoledronic acid in pediatric metabolic bone disorders

Sasigarn A Bowden  1 , John D Mahan  2
Affiliations
Review

Zoledronic acid in pediatric metabolic bone disorders

Sasigarn A Bowden et al. Transl Pediatr. 2017 Oct.

Abstract

Zoledronic acid (ZA), a highly potent intravenous bisphosphonate (BP), has been increasingly used in children with primary and secondary osteoporosis due to its convenience of shorter infusion time and less frequent dosing compared to pamidronate. Many studies have also demonstrated beneficial effects of ZA in other conditions such as hypercalcemia of malignancy, fibrous dysplasia (FD), chemotherapy-related osteonecrosis (ON) and metastatic bone disease. This review summarizes pharmacologic properties, mechanism of action, dosing regimen, and therapeutic outcomes of ZA in a variety of metabolic bone disorders in children. Several potential novel uses of ZA are also discussed. Safety concerns and adverse effects are also highlighted.

Keywords: Zoledronic acid (ZA); acute phase reaction (APR); bone mineral density (BMD); fragility fractures; hypercalcemia; metabolic bone disease; osteonecrosis (ON); osteoporosis.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: SA Bowden is a member of the advisory board for Novartis. JD Mahan has no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Chemical structures of BP and ZA. (A) General structure of BP. Side chain R1 and R2 can be modified to alter the hydroxyapatite binding capability and the potency of BP; (B) structure of ZA with an imidazole-ring side chain containing 2 critically positioned nitrogen atoms. BP, bisphosphonate; ZA, zoledronic acid.
See this image and copyright information in PMC

References

    1. Chen JS, Sambrook PN. Antiresorptive therapies for osteoporosis: a clinical overview. Nat Rev Endocrinol 2011;8:81-91. 10.1038/nrendo.2011.146 - DOI - PubMed
    1. Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 2008;83:1032-45. 10.4065/83.9.1032 - DOI - PMC - PubMed
    1. Green JR. Zoledronic acid: pharmacologic profile of a potent bisphosphonate. J Organomet Chem 2005;690:2439-48. 10.1016/j.jorganchem.2004.09.069 - DOI
    1. Nancollas GH, Tang R, Phipps RJ, et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 2006;38:617-27. 10.1016/j.bone.2005.05.003 - DOI - PubMed
    1. Green JR, Rogers MJ. Pharmacologic profile of zoledronic acid: A highly potent inhibitor of bone resorption. Drug Dev Res 2002;55:210-24. 10.1002/ddr.10071 - DOI

LinkOut - more resources